摘要
目的研究对2型糖尿病(type 2 diabetes mellitus,T2DM)合并消化性溃疡(peptic ulcer,PU)患者采取药物治疗的效果。方法于2021年1—12月尤溪县总医院消化内科收治的T2DM合并PU患者中随机抽取86例,分为两组,每组43例。对照组采取二甲双胍+四联疗法,观察组采取阿卡波糖+达格列净+四联疗法,对比两组治疗效果。结果观察组患者FPG(7.95±1.18)mmol/L、2 hPG(8.52±1.22)mmol/L、HbA1c(8.22±1.19)%,显著低于对照组的FPG(8.80±1.20)mmol/L、2 hPG(9.34±1.18)mmol/L、HbA1c(9.16±1.26)%,差异有统计学意义(P<0.05)。观察组治疗有效率(95.35%)明显优于对照组(74.42%),差异有统计学意义(P<0.05)。两组不良反应对比,差异无统计学意义(P>0.05)。结论对T2DM合并PU患者采取阿卡波糖+达格列净+四联疗法进行干预,更有利于降低血糖水平,提高综合治疗效果,且不会增加药物不良反应。
Objective To investigate the effect of drug treatment for Type 2 diabetes mellitus(T2DM)with peptic ulcer(PU).Methods From January to December 2021,86 patients with T2DM and PU were randomly selected from the Department of Gastroenterology of Youxi County General Hospital,and were divided into two groups,43 patients in each group.The control group was treated with metformin+quadruple therapy,and the observation group was treated with acarbose+dapagliflozin+quadruple therapy.The therapeutic effect of the two groups was compared.Results FPG(7.95±1.18)mmol/L,2 hPG(8.52±1.22)mmol/L,HbA1c(8.22±1.19)%in the observation group were significantly lower than FPG(8.80±1.20)mmol/L,2 hPG(9.34±1.18)mmol/L,HbA1c(9.16±1.26)%in the control group,the difference was statistically significant(P<0.05).The effective rate of the observation group was 95.35%,which was significantly better than that of the control group 74.42%,the difference was statistically significant(P<0.05).There was no statistically significant difference in adverse reaction between the two groups(P>0.05).Conclusion The intervention of acarbose+daggligin+quadruple therapy for T2DM patients with PU is more conducive to reducing blood glucose level,improving the comprehensive treatment effect,and will not increase adverse drug reactions.
作者
蒋际宝
JIANG Jibao(Department of Gastroenterology,Youxi County General Hospital,Sanming,Fujian Province,365100 China)
出处
《糖尿病新世界》
2022年第22期82-85,共4页
Diabetes New World Magazine
